ACSL4 and metabolic dysfunction-associated steatohepatitis: In line with a disease-aggravating role of ferroptosis during chronic liver injury, hepatocyte-specific deletion of Acsl4 was recently shown to reduce disease severity, in particular liver steatosis and fibrosis, in two diet-based mouse models of NASH [45].